Last reviewed: July 2026 · SecondFyre Editorial

HRT in Plain English: What It Is, What the Evidence Actually Says, and How to Have the Conversation

There is probably no topic in women’s health more surrounded by fear, confusion, and outdated information than hormone replacement therapy.

Women who need it are afraid to take it. Women who are taking it feel guilty about it. Doctors who don’t specialize in menopause are still using risk frameworks from 2002. And in the middle of all of it are real women having a genuinely terrible time — with hot flashes, insomnia, brain fog, joint pain, mood crashes, and vaginal atrophy — who have been told to manage with a fan and some sage tea.

This piece is the plain-English breakdown. What HRT is. What the science actually says. Who it’s for and who it isn’t for. And how to talk to your doctor when you’ve decided you want to explore it.

What HRT Actually Is

Hormone replacement therapy — also called hormone therapy (HT), menopausal hormone therapy (MHT), or HRT depending on who you’re asking — refers to taking hormones, typically estrogen and/or progesterone, to replace the hormones your ovaries stop producing during the menopause transition.

That’s it. It is supplementing what your body is no longer making enough of.

The main hormones involved:

Estrogen. The primary hormone that declines in menopause. Responsible for most of the classic menopause symptoms — hot flashes, vaginal dryness, sleep disruption, brain fog, joint pain, mood changes, and more. Estrogen therapy alone is used by women who have had a hysterectomy (removal of the uterus).

Progesterone (or progestogen). Used alongside estrogen in women who still have their uterus. Estrogen alone causes the uterine lining to thicken; progesterone is added to protect against endometrial cancer. There is a meaningful difference between body-identical progesterone (micronised progesterone, e.g. Utrogestan) and synthetic progestogens (progestins), which we’ll come to.

Testosterone. Less commonly discussed but increasingly recognized as relevant to menopause — testosterone declines in women too, and low levels are associated with loss of libido, fatigue, and reduced energy. Available as an add-on therapy in some countries, though licensing is limited.

The 2002 Problem — and Why We’re Still Living With It

In 2002, a large US study called the Women’s Health Initiative (WHI) published interim results suggesting that combined HRT increased the risk of breast cancer, heart disease, stroke, and blood clots. The study was stopped early. The results made international headlines. HRT prescriptions dropped by half almost overnight.

Women stopped taking it. Doctors stopped prescribing it. And a generation of women going through menopause were told to avoid it, manage symptoms naturally, and wait it out.

Here is what is now known about the WHI study that was not widely communicated to the public:

The average age of participants was 63. Most were more than 10 years past menopause. The study used oral conjugated equine estrogen (from horse urine) combined with a synthetic progestogen called medroxyprogesterone acetate — not the body-identical hormones used in modern HRT. The risks identified were primarily relevant to women starting HRT late, not to women starting it during perimenopause or early menopause.

The WHI itself subsequently re-analysed its data by age group and found that women who started HRT under 60, or within 10 years of menopause, had a different — and much more favourable — risk profile than the older group. The study also found that estrogen-only HRT (for women without a uterus) was associated with a reduction in breast cancer risk.

None of this received the same press coverage as the original 2002 headlines.

What the Current Evidence Says

Guidelines from The Menopause Society (North America), the British Menopause Society, and the European Menopause and Andropause Society now broadly agree on the following:

For women under 60 who are within 10 years of menopause and have no specific contraindications, the benefits of HRT outweigh the risks for most women.

The benefits are well-established:

• Significant reduction in hot flashes and night sweats (75-90% reduction in most women)
• Improved sleep quality
• Resolution of vaginal dryness and genitourinary symptoms
• Improved mood stability
• Reduced risk of osteoporosis and fractures
• Cardiovascular protection when started early (“timing hypothesis”)
• Possible reduction in risk of type 2 diabetes
• Possible cognitive protective effects when started during the transition window

The risks, in context:

Breast cancer. The most cited concern. The increased risk associated with combined HRT (estrogen + synthetic progestogen) is roughly equivalent to the increased risk associated with drinking one glass of wine a day. Body-identical progesterone (micronised progesterone) appears to carry a lower breast cancer risk than synthetic progestogens — the research on this is meaningful and worth discussing with your doctor. Women on estrogen-only HRT may have a reduced risk of breast cancer compared to non-users.

Blood clots (VTE). Oral estrogen increases the risk of venous thromboembolism. Transdermal estrogen (patch, gel, or spray delivered through the skin) does not carry the same increased risk, because it bypasses the liver. This is one of the strongest reasons modern guidance favours transdermal over oral routes.

Stroke. Oral estrogen carries a small increased stroke risk. Again, transdermal estrogen does not appear to carry this risk.

The method of delivery matters enormously — and this is something many doctors who trained in the post-WHI era don’t fully appreciate.

Types of HRT

Transdermal (through the skin). Patches, gels, and sprays. The preferred route for most women because it bypasses the liver, minimising blood clot and stroke risk. Patches are changed every 1-3 days. Gels and sprays are applied daily. This is what most menopause specialists now recommend as first-line.

Oral. Tablets. More convenient for some, but associated with higher clot and stroke risk as noted above. Still appropriate for some women depending on individual circumstances.

Local / topical (vaginal). Low-dose estrogen delivered directly to vaginal tissue via cream, ring, or pessary. Used specifically for genitourinary symptoms — vaginal dryness, pain with sex, urinary symptoms. The systemic absorption is very low; this can be used by most women including those who cannot use systemic HRT.

Body-identical / regulated bioidentical. This refers to hormones with the same molecular structure as those produced by the human body — 17-beta estradiol and micronised progesterone. Most modern transdermal HRT is body-identical. “Compounded bioidentical” HRT (custom-mixed by a compounding pharmacy) is different — it is not regulated in the same way and its safety and dosing consistency has not been established. The two are not the same thing.

Who HRT Is Not Suitable For

There are genuine contraindications. HRT is generally not recommended for women with:

• A current or recent diagnosis of hormone-receptor-positive breast cancer
• Active or recent blood clot (VTE) history — though transdermal options may be considered case by case
• Untreated endometrial cancer
• Active liver disease
• Unexplained vaginal bleeding (which should be investigated before starting HRT)
• Certain cardiovascular conditions — assessed on individual basis

Note: a family history of breast cancer is not an automatic contraindication. This is a common misconception. The risk assessment should be individualised, and many women with family history can safely use HRT. This is a conversation to have with a doctor who specialises in menopause, not a GP who may be applying general rules without the context to interpret them.

How Long Can You Take It?

There is no fixed maximum duration. Current guidance from The Menopause Society states that duration of use should be based on individual assessment, quality of life, and risk. Annual review is standard. Many women take HRT for 5 years; some take it for longer; some choose to continue indefinitely after weighing risks and benefits with their doctor.

“You can only take it for 5 years” is not current guidance. If your doctor says this, ask them to cite the source and engage with the updated evidence.

What About “Natural” Alternatives?

Phytoestrogens, black cohosh, evening primrose, sage — these are covered in the hot flashes guide. The honest answer: for severe or frequent symptoms, plant-based supplements do not deliver what HRT delivers. They may offer modest benefit for mild symptoms. They are not equivalent.

Choosing not to use HRT is completely valid — but it should be an informed choice, not a choice driven by fear of a 2002 study that has since been substantially reinterpreted.

Having the Conversation with Your Doctor

Many women report being brushed off, told they’re “too young,” told it’s “too risky,” or given outdated information. Here is language that may help:

“I’ve been reading the current guidelines from The Menopause Society and the British Menopause Society, and I understand that for women my age within 10 years of menopause, the benefit-risk profile of HRT has been re-evaluated. I’d like to have a proper assessment of whether I’m a candidate. If there are specific contraindications for me, I’d like to understand them.”

If your GP is unwilling to engage with current evidence, you have the option to seek a menopause specialist. In the UK, the British Menopause Society has a directory of accredited menopause specialists. In the US, the Menopause Society (formerly NAMS) maintains a practitioner finder.

You are allowed to advocate for yourself. You are allowed to be informed. You are allowed to decide that your quality of life matters.

The Bottom Line

HRT is not the dangerous, cancer-causing treatment that 2002 headlines made it. For most women under 60, within 10 years of menopause, with no specific contraindications, it is the most effective treatment for menopause symptoms and carries a risk profile that has been substantially revised since the WHI study.

Transdermal delivery. Body-identical hormones. Individualised assessment. These are the markers of current good practice.

You deserve accurate information. You deserve a clinician who will give it to you. And you deserve to make a decision based on what the evidence actually says — not what it said 24 years ago.

This is not your slow down. This is your second fyre.